MedPath

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Completed
Conditions
Hypertension
Interventions
Registration Number
NCT00879411
Lead Sponsor
Boehringer Ingelheim
Brief Summary

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
670
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
arterial hypertensionMicardis-
Primary Outcome Measures
NameTimeMethod
Efficacy (Change of Systolic Blood Pressure)baseline to 8 weeks

Change from baseline in 24h systolic blood pressure (BP) at week 8

Efficacy (Change of Diastolic Blood Pressure)baseline to 8 weeks

Change from baseline in 24h diastolic blood pressure (BP) at week 8

Secondary Outcome Measures
NameTimeMethod
Overall Tolerability Scale8 weeks

Safety and tolerability of Micardis® in the treatment of patients with hypertension over 8 weeks, using 10 point Likert scale with worst score=1, best score=10

© Copyright 2025. All Rights Reserved by MedPath